blosozumab
mAbexperimental
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. — Wikipedia
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT01742078)
Timeline
Indications
Mechanism of action
- SclerostinINHIBITOR
SOST inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBlosozumab ↗
- ChEMBLCHEMBL2109572 ↗
- ChEMBLCHEMBL1742993 ↗
Also known as
- anti-sclerostin
- blosozumab
- blosozumab
- blosozumab
- ly2541546
- ly-2541546
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05391776 | Phase 1 | Apr 28, 2022 | — |
| NCT02337387 | Phase 1 | Jan 1, 2015 | Eli Lilly |
| NCT02109042 | Phase 1 | Apr 1, 2014 | Eli Lilly |
| NCT01144377 | Phase 2 | Aug 1, 2010 | Eli Lilly |
| NCT01742091 | Phase 1 | Sep 1, 2009 | Eli Lilly |
| NCT01742078 | Phase 1 | Jun 1, 2008 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1